This past week, CTM covered the following issues.

Beijing issued a new set of rules governing how companies assess data security risks and introducing a full-chain state oversight especially for operators that process important data.

Following a burst of high-level diplomacy, China's Ministry of Commerce (MOFCOM) offered comments on the new bilateral trade consultation mechanisms with the EU and Germany, an export-boosting campaign in the UK, and advancing two-way agricultural trade targets with the U.S.

MOFCOM also announced that it will impose a 73.5% provisional anti-dumping rate on pea starch imports from Canada.

And MOFCOM blacklisted 40 Japanese defense, aerospace, and technology entities, escalating a diplomatic and economic confrontation over Tokyo's recent military and defense policy shifts.

Chinese-linked automaker Polestar announced that it has not been granted authorization by the U.S. Department of Commerce to sell "connected vehicles" in the United States, and therefore would be leaving the U.S. market as of the 2027 model year.

New legislation introduced in both the U.S. House and Senate would establish an oversight body to scrutinize any Chinese investment made pursuant to a proposed U.S.-China Board of Investment.

In legal filings this week, Chinese tech company Alibaba laid out its case for an injunction in relation to a Trump administration decision to designate it as a "Chinese Military Company," focusing on first amendment speech issues; and Chinese biotech company WuXi AppTec Co., Ltd. made its case for asking a court to enjoin a Trump administration decision to designate it as a "Chinese Military Company."

EU and Chinese trade officials met, and settled on a roadmap for future talks that seeks to produce "tangible results" by October. Separately, the EU is now moving ahead with new tariffs to protect its steel industry from global overcapacity, a move which has already been a source of irritation for China.

At a European Parliament meeting, a European Commission official provided an update on the status of the first case under the EU's International Procurement Instrument (IPI), which addressed barriers in the Chinese medical devices market.